Third reincarnation of deal will include target discovery and validation services.
BioFocus has extended its drug discovery collaboration with Amgen into 2012 and will earn $2.6 million in research fees over the first year of the new agreement. The new contract has also been expanded to incorporate the provision of target discovery and validation services by BioFocus in support of Amgen’s therapeutic programs. BioFocus could in addition receive access fee and success-based milestone payments.
The firms’ collaboration to identify new molecules against a range of disease targets was initiated in 2002 and extended in 2006 and again in 2008. “With each extension, Amgen has expanded the range of services provided by BioFocus, with target discovery being included this time around,” remarks Chris Newton, Ph.D., svp at parent firm Galapagos’ services division.